These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 23574506)

  • 1. Repairing mutated proteins--development of small molecules targeting defects in the cystic fibrosis transmembrane conductance regulator.
    Merk D; Schubert-Zsilavecz M
    Expert Opin Drug Discov; 2013 Jun; 8(6):691-708. PubMed ID: 23574506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls.
    Bell SC; De Boeck K; Amaral MD
    Pharmacol Ther; 2015 Jan; 145():19-34. PubMed ID: 24932877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Progress in the Discovery and Development of Small-Molecule Modulators of CFTR.
    Kym PR; Wang X; Pizzonero M; Van der Plas SE
    Prog Med Chem; 2018; 57(1):235-276. PubMed ID: 29680149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into the mechanisms underlying CFTR channel activity, the molecular basis for cystic fibrosis and strategies for therapy.
    Kim Chiaw P; Eckford PD; Bear CE
    Essays Biochem; 2011 Sep; 50(1):233-48. PubMed ID: 21967060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
    Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
    Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repairing the basic defect in cystic fibrosis - one approach is not enough.
    Farinha CM; Matos P
    FEBS J; 2016 Jan; 283(2):246-64. PubMed ID: 26416076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cystic Fibrosis: Proteostatic correctors of CFTR trafficking and alternative therapeutic targets.
    Hanrahan JW; Sato Y; Carlile GW; Jansen G; Young JC; Thomas DY
    Expert Opin Ther Targets; 2019 Aug; 23(8):711-724. PubMed ID: 31169041
    [No Abstract]   [Full Text] [Related]  

  • 9. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
    Solomon GM; Marshall SG; Ramsey BW; Rowe SM
    Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized medicine in cystic fibrosis: dawning of a new era.
    Clancy JP; Jain M
    Am J Respir Crit Care Med; 2012 Oct; 186(7):593-7. PubMed ID: 22723294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-molecule drugs for cystic fibrosis: Where are we now?
    Laselva O; Guerra L; Castellani S; Favia M; Di Gioia S; Conese M
    Pulm Pharmacol Ther; 2022 Feb; 72():102098. PubMed ID: 34793977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new 9-alkyladenine-cyclic methylglyoxal diadduct activates wt- and F508del-cystic fibrosis transmembrane conductance regulator (CFTR) in vitro and in vivo.
    Boucherle B; Bertrand J; Maurin B; Renard BL; Fortuné A; Tremblier B; Becq F; Norez C; Décout JL
    Eur J Med Chem; 2014 Aug; 83():455-65. PubMed ID: 24992073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HGF stimulation of Rac1 signaling enhances pharmacological correction of the most prevalent cystic fibrosis mutant F508del-CFTR.
    Moniz S; Sousa M; Moraes BJ; Mendes AI; Palma M; Barreto C; Fragata JI; Amaral MD; Matos P
    ACS Chem Biol; 2013 Feb; 8(2):432-42. PubMed ID: 23148778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of cystic fibrosis treatment.
    Carter SC; McKone EF
    Pharmacogenomics; 2016 Aug; 17(13):1453-63. PubMed ID: 27490265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetics of cystic fibrosis: CFTR mutation classifications toward genotype-based CF therapies.
    Fanen P; Wohlhuter-Haddad A; Hinzpeter A
    Int J Biochem Cell Biol; 2014 Jul; 52():94-102. PubMed ID: 24631642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New therapies for cystic fibrosis targeting the CFTR gene or the CFTR protein].
    Hubert D; Bui S; Marguet C; Colomb-Jung V; Murris-Espin M; Corvol H; Munck A
    Rev Mal Respir; 2016 Oct; 33(8):658-665. PubMed ID: 26806675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological therapy for cystic fibrosis: from bench to bedside.
    Becq F; Mall MA; Sheppard DN; Conese M; Zegarra-Moran O
    J Cyst Fibros; 2011 Jun; 10 Suppl 2():S129-45. PubMed ID: 21658632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New drugs for cystic fibrosis.
    Wilschanski M; Kerem E
    Expert Opin Investig Drugs; 2011 Sep; 20(9):1285-92. PubMed ID: 21745147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of Cystic Fibrosis with CFTR Modulators].
    Tümmler B
    Pneumologie; 2016 May; 70(5):301-13. PubMed ID: 26894479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cystic fibrosis: molecular update and clinical implications].
    Orozco L; Chávez M; Saldaña Y; Velázquez R; Carnevale A; González-del Angel A; Jiménez S
    Rev Invest Clin; 2006; 58(2):139-52. PubMed ID: 16827266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.